

HTG MOLECULAR DIAGNOSTICS, INC
Form SC 13G
November 22, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. ___)*
HTG Molecular Diagnostics, Inc.
(Name of Issuer)
Common Stock, \$0.001 par value
(Title of Class of Securities)
40434H 104
(CUSIP Number)
November 17, 2016
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G
CUSIP No. 40434H 104

Names of Reporting

- 1 Person:
QIAGEN N.V.
Check the appropriate box
if a member of a Group
2 (see instructions)
(a)
(b)
3 SEC Use Only

Citizenship or Place of
4 Organization

- The Netherlands
5 ~~Number~~ of ~~Shares~~ Voting Power
of 833,333
6 ~~Number~~ of ~~Shares~~ Shared Voting Power
Beneficially
7 ~~Number~~ of ~~Shares~~ Dispositive Power
by 833,333
8 ~~Number~~ of ~~Shares~~ Shared Dispositive Power
Reporting
Person
With:

- Aggregate Amount
9 Beneficially Owned by
Each Reporting Person
833,333
Check box if the aggregate
amount in row (9) excludes
10 certain shares (See
Instructions)

Percent of class represented
11 by amount in row (9)
10.6%
Type of Reporting Person
12 (See Instructions)
FI

SCHEDULE 13G
CUSIP No. 40434H 104

Names of Reporting
Person:
1 QIAGEN North American
Holdings, Inc.
Check the appropriate box
if a member of a Group
2 (see instructions)
(a)
(b)
3 SEC Use Only

Citizenship or Place of
4 Organization
California
Number of ~~Shares~~ Voting Power
5 of 0⁽¹⁾
Number of ~~Shares~~ Shared Voting Power
6 Beneficially
Owned ~~by~~ Dispositive Power
7 by 0⁽¹⁾
Number of ~~Shares~~ Shared Dispositive Power
8 Reporting
Person
With:

Aggregate Amount
9 Beneficially Owned by
Each Reporting Person
0⁽¹⁾
Check box if the aggregate
amount in row (9) excludes
10 certain shares (See
Instructions)

Percent of class represented
11 by amount in row (9)

Type of Reporting Person
12 (See Instructions)
CO

⁽¹⁾The 833,333 shares of
Common Stock of the Issuer
are held of record by
QIAGEN North American
Holdings, Inc., a
wholly-owned subsidiary of
QIAGEN N.V.

Item 1.

- (a) Name of Issuer: HTG Molecular Diagnostics, Inc.
- (b) Address of Issuer's Principal Executive Offices: 3430 E. Global Loop, Tucson, Arizona 85706

Item 2.

- (a) Name of Person Filing: QIAGEN N.V.
- (b) Address of Principal Business Office or, if None, Residence: Hulsterweg 82, 5912 PL Venlo, The Netherlands
- (c) Citizenship: The Netherlands
- (d) Title and Class of Securities: Common Stock, par value \$0.001 per share.
- (e) CUSIP No.: 40434H 104

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is
a:

Not applicable as this Schedule is filed pursuant to Rule 13d-1(c).

Item 4. Ownership

- (a) Amount Beneficially Owned: 833,333
- (b) Percent of Class: 10.6%
- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote: 833,333
 - (ii) Shared power to vote or to direct the vote:
 - (iii) Sole power to dispose or to direct the disposition of: 833,333
 - (iv) Shared power to dispose or to direct the disposition of:

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of more than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

The shares of Common Stock of the Issuer were acquired by and are held of record by QIAGEN North American Holdings, Inc., a wholly owned subsidiary of QIAGEN N.V.

Item 8. Identification and classification of members of the group.

See Item 7.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 22, 2016

QIAGEN
N.V.
QIAGEN
North
American
Holdings,
Inc.

By: /s/ Roland
Sackers
Roland
Sackers
Chief
Financial
Officer